TABLE 1.

Humoral and T-cellular response rates 6 months (T3) after the 1st vaccination.

Variable	Category	3x BNT162b2	2x BNT162b2, 1x 1273	2x 1273, 1x BNT162b2	3x 1273	2x mRNA, 1x vector	p_Value	2x mRNA
Patient number	N	57	22	16	63	8		67
Humoral response
IgG-Ab or IgA-Ab SpikeS1 positive	n of total n (%)	17/57 (29.8%)	8/22 (36.4%)	8/16 (50%)	31/63 (49.2%)	1/8 (12.5%)	0.092	11/67 (16.4%)
IgG-Ab Spike S1 positive	n of total n (%)	12/57 (21.1%)	6/22 (27.3%)	7/16 (43.8%)	29/63 (46%)	1/8 (12.5%)	0.025	10/67 (14.9%)
RBD positive	n of total n (%)	11/57 (19.3%)	5/22 (22.7%)	3/16 (18.8%)	20/63 (31.7%)	1/8 (12.5%)	0.464	6/67 (9%)
IgA-Ab SpikeS1 positive	n of total n (%)	12/57 (21.1%)	6/22 (27.3%)	4/16 (25%)	21/63 (33.3%)	1/8 (12.5%)	0.524	7/67 (10.4%)
Interferon-γ release assay (IGRA)—T-cellular response
IGRA positive	n of total n (%)	1/16 (6.2%)	0/7 (0%)	0/0 (0%)	6/16 (37.5%)	1/7 (14.3%)	0.06	5/25 (20%)

Humoral vaccination responses were assessed as positive when de novo production of the anti-SpikeS1 IgG and (anti-SpikeS1 IgA or IgG endpoint of the original DIA-Vacc study)/or IgA or IgG protein or anti-RBD IgG subunit was above positivity level. A positive T-cellular response to vaccination as assessed by interferon-γ release assay (IGRA) turned from a negative result on T0 to positive on T3, respectively (≥100 mIU/ml, as being recommended by the manufacturers). For this evaluation, all participants with asymptomatic* or documented symptomatic** COVID-19 disease before and during vaccination up to T3 (6 months) were excluded.

BNT162b2 = BNT162b2-mRNA or tozinameran or brand name Comirnaty; 1273 = 1273-mRNA or brand name Spikevax.

*Asymptomatic COVID-19 disease definition–neither knowledge nor symptoms of COVID-19 disease, but IgG-antibody reaction to nucleocapsid (T0, T2, or T3) or the Spike protein subunit S1 (only T0) of the SARS-CoV-2 virus is positive.

**Symptomatic COVID-19 disease definition–SARS-CoV-2 PCR positive patients with clinical symptoms.